Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a reliable RP-HPLC method for the simultaneous estimation of Spironolactone and Hydrochlorothiazide, which was validated as accurate, precise, and robust for pharmaceutical applications.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This article argues that prolactin may have a role in sebaceous gland function and suggests it could be a potential target for treating skin conditions, but reports no new clinical findings.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This study found that combining low-dose spironolactone with metformin provided greater clinical benefits and improved treatment compliance in women with PCOS compared to either drug alone.

This study demonstrated that regular use of LactoSporin cream for 10 weeks significantly reduced wrinkles and fine lines in healthy female participants, although improvements in skin elasticity and hydration were not significantly better than placebo when measured by certain instruments.

This case report highlighted an instance of lichen spinulosus emerging as a new cutaneous sequela in a boy following toxic epidermal necrolysis, responding to treatment with ammonium lactate.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

This study found that in newborn rats treated with caffeine, progesterone increased apnoea frequency by inhibiting breathing, suggesting it may not be suitable for preterm neonates without addressing allopregnanolone's effects.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This study reported a significant increase in the use of spironolactone for treating acne and hidradenitis suppurativa in female adolescents, noting a 2- to 3-fold rise in prescriptions and suggesting improved tolerance compared to adults, though its efficacy in adolescents is less pronounced.

This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.

This study reported that extended-release valproate significantly reduced seizure frequency and improved quality of life in epilepsy patients over six months, despite some adverse effects like weight gain and tremor.

This study reported that hypoglycemia is a more frequent complication in type 1 diabetes patients than in type 2, primarily due to inappropriate insulin and anti-diabetes medication dosing.

The study found that cyproterone acetate could be released over 15 days using coconut oil mixed with certain wax inhibitors, though further safety studies are needed.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found that the polyherbal cough syrup Linkus reduced cough reflexes without causing observed toxicity in rats, suggesting it may be an effective and safe option.

Among cultured sebocytes, this study found that bilobetin significantly inhibited lipid production induced by IGF-1, suggesting potential for use in acne treatment.

This study observed that dermatological and hair changes, like skin sagging and hair shedding, commonly occur early during weight loss with GLP-1 receptor agonists, highlighting the need for tailored dermatological care alongside treatment.

This study found that norethindrone and levonorgestrel affected Arabidopsis thaliana root growth differently depending on concentration, with levonorgestrel being highly active and most effective at promoting taproot growth at low doses.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This study suggests that in late pregnancy, allopregnanolone induces opioid inhibition of oxytocin secretion in response to immune challenge, potentially minimizing the risk of preterm labor in rats.

In this study, low-dose spironolactone effectively reduced hirsutism in women and stopped hair loss in one woman with alopecia areata, without significant side effects over 12 menstrual cycles.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.